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A new B-Raf inhibitor combo for advanced melanoma
Marjam-Jeanette Barysch, Joanna Mangana and Reinhard Dummer
During the last decade, several new treatment 
modalities have been developed, that impressively 
improved survival and quality of life in patients with 
advanced melanoma, who did not face any progress since 
more than 50 years [1]. These revolutionary developments 
are incomparable with other cancer types and additional 
progress is anticipated. In this continuous breakthrough, 
combination treatments have shown to facilitate superior 
treatment responses compared to monotherapies. The 
combination of checkpoint-inhibitors (CI) consisting of 
CTLA4 blockade with ipilimumab plus PD1 blockade 
with nivolumab leads to a significant higher overall-
response of 58% with 19% of patients achieving complete 
responses [2]. In the targeted therapy field, combination of 
tyrosine kinase inhibitors (TKI) consisting of BRAF- plus 
MEK inhibitor (BRAFi and MEKi) (dabrafenib/trametinib 
or vemurafenib/cobimetinib) led to improved overall (OS) 
and progression-free survival (PFS) [3, 4]. Interestingly, 
the addition of MEKi ameliorates tolerability and reduces 
the occurrence of on -target BRAFi-related cutaneous 
toxicities driven by the paradoxical pathway activation. 
However, approximately 40%–50% of melanoma 
patients treated first line with the above modern treatment 
combinations, either fail to elicit an anti-tumor response 
(primary resistance) or will eventually progress at 12 
months (secondary resistance); hence, further strategies 
are mandatory.Encorafenib is an APT-competitive 
BRAFi, showing a similar IC50 (half-maximal inhibitory 
concentration) for wild-type BRAF, V600E mutant and 
CRAF in cell-free biochemical assays, which might 
be relevant for reducing the paradoxical activation of 
MAPK pathway. It presents a longer dissociation half-life 
than dabrafenib and vemurafenib. In addition to its high 
potency and affinity, encorafenib is also a highly specific 
inhibitor of BRAF [5]. The efficacy of encorafenib in 
combination with the ATP-non-competitive MEK inhibitor 
binimetinib was investigated in the phase III clinical 
trial (COLUMBUS) and presented excellent efficacy in 
comparison to other targeted treatment combinations and 
yet was well tolerated. Patients were randomized 1:1:1 
to COMBO450 (encorafenib 450mg+binimetinib 45mg) 
(n = 192), ENCO300 (encorafenib 300mg) (n = 194), or 
VEM (vemurafenib) (n = 191). At a median follow up of 
16.6 months, the combination therapy led to a significant 
improvement in OS and in disease recurrence with a 
median PFS of 14.9 months compared to 7.3 months in 
the vemurafenib group (hazard ratio 0.54) [6].
At median follow up of 21.5 months, median OS 
was reported as 33.6 months (95% CI, 24.4-39.2) with 
COMBO450, 23.5 months (95% CI, 19.6-33.6) with 
ENCO300, and 16.9 months (95% CI, 14.0-24.5) with 
vemurafenib. The combination therapy with encorafenib 
plus binimetinib was better tolerated with fewer grade 
3 or 4 adverse events (AEs) and a lower rate of drug 
discontinuation compared to ENCO300 and VEM. Lower 
rates of other class specific side effects such as pyrexia 
and photosensitivity were also observed, highlightening 
its’ excellent tolerability. Interestingly, and despite 
the numerical differences in the OS and PFS between 
COMBO450, vemurafenib/combimetinib in the co-BRIM 
and dabrafenib/trametinib in the Combi-D, the reported 
HR for OS was similar (0.61 versus 0.76 versus 0.68 
respectively) [6, 7].
Based on the above findings, FDA approved the 
combination of encorafenib and binimetinib for the 
treatment of metastatic melanoma harboring the BRAF 
mutation, adding another drug combination in the pipeline. 
Whether it will substitute the current BRAF/MEKi 
options or be restricted for patients, experiencing pyrexia 
or photosensitivity under the already existing BRAF/
MEKi combinations remains open. However, in order to 
stay competitive, further trials are requisite. Particularly 
combination therapy with checkpoint inhibitors are 
required, regarding multiple ongoing studies investigating 
combination treatments with rival BRAF/MEK-inhibitors 
and checkpoint inhibitors - either simultaneously or in 
sequence (NCT02130466, NCT02967692, NCT02224781 
and NCT02908672). Furthermore, comparative 
prospective trials exploring the efficacy on brain 
metastases are needed as combined checkpoint inhibition 
or targeted therapy has shown excellent response in this 
patients collective already [8, 9].
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